If you’re one of the many people affected by the drug Elmiron, you’ll be happy to know that there are now some great updates on the case and that you may be eligible for compensation. If you or someone you know has been diagnosed with vision and eye problems, it’s best to file a lawsuit as soon as possible.
If you or someone you know wants an update on the Elmiron lawsuit, and wants to know whether or not you can file for compensation, keep reading to learn more!
click here – 4 Marketing Tactics That Need More Attention
What is Pentosan Polysulfate Sodium?
Pentosan Polysulfate Sodium (PPS) is the active ingredient in Elmiron. It was first approved by the FDA in 1996 to treat interstitial cystitis, a bladder condition. However, since its approval, Elmiron has become increasingly prescribed off-label to treat other conditions such as endometriosis, pelvic pain, and even arthritis.
PPS is a man-made chemical that is designed to mimic the properties of heparin. Heparin is a natural anticoagulant (blood thinner) that is found in our bodies. When PPS enters our system, it binds to proteins in our cells and prevents blood clots from forming.
Pentosan Polysulfate Sodium has been found to be an effective treatment for interstitial cystitis and other conditions. However, recent studies have linked Elmiron to vision and eye problems. These side effects were first discovered in 2018 by a group of ophthalmologists. The study showed a direct correlation between Elmiron and maculopathy, a condition that affects the central area of the retina.
What is Maculopathy?
Maculopathy is an eye disease that affects the macula, the central area of the retina. The retina is the light-sensitive tissue at the back of the eye. The macula is responsible for our central vision.
People with maculopathy may experience symptoms such as:
- Blurry vision
- Difficulty reading
- Decreased color vision
- Central scotoma (blind spot in the center of their vision)
If maculopathy is left untreated, it can lead to central vision loss.
click here – The Aims Of Human Capital Management
Big Updates in 2022
Sadly, Elmiron failed to warn patients about the risk of vision problems, and didn’t attach a warning label to its medicine until 2022. As a result, many people have suffered serious side effects. If you or someone you know has been affected by Elmiron, it’s important to know that there are some big updates in the case!
As of January 2022, an MDL (multi-district litigation) has been filed in the U.S. District Court for the District of New Jersey. This means that all federal Elmiron lawsuits will be consolidated into one court.
The first bellwether trial is set to begin in January 2023. A bellwether trial is a test case that is used to gauge how juries will respond to certain evidence and arguments. The outcome of a bellwether trial can often be used to settle other similar cases.
If you or someone you know has been affected by Elmiron, it’s important to stay updated on the case! You may be eligible for compensation for your injuries. An experienced Elmiron lawyer can help you understand your legal options and get the compensation you deserve.
What to Do In the Meantime
If you or someone you know has been diagnosed with maculopathy, it’s important to see an experienced eye doctor as soon as possible. Maculopathy is a progressive disease, and early treatment is essential to preserving vision.
In the meantime, if you or someone you know has been affected by Elmiron, don’t hesitate to contact an experienced attorney who will help file your case and consolidate it into the MDL. You may be eligible for compensation for your injuries, and an experienced lawyer will fight to get you the maximum amount of money possible.